VF
RCUS icon

Virtu Financial’s Arcus Biosciences RCUS Stock Holding History

Virtu Financial’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$211K Buy
+9,768
New +$211K 0.01% 1004
2021
Q2 		– Sell
-24,321
Closed -$683K – 1981
2021
Q1 		$683K Buy
+24,321
New +$846K 0.05% 369

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Virtu Financial's RCUS Position: Q1 2026 in Review

Virtu Financial opened a new position in Arcus Biosciences (RCUS) in Q1 2026: 9,768 shares worth $211K. The stake represents 0.01% of the portfolio and ranks #1004 among its holdings. This is a return to the name: Virtu Financial previously reported a position in RCUS as recently as Q1 2021.

Virtu Financial first reported a position in RCUS in Q1 2021 and has held it in 2 quarters since. The position peaked at $683K in Q1 2021. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Virtu Financial held 9,768 shares of Arcus Biosciences worth $211K as of Q1 2026.
  • Arcus Biosciences was a new Virtu Financial position in Q1 2026.
  • Arcus Biosciences made up 0.01% of Virtu Financial's portfolio in Q1 2026, its #1004 holding.
  • Virtu Financial first reported a position in Arcus Biosciences in Q1 2021 and has held it in 2 quarters since.
  • Virtu Financial's Arcus Biosciences position peaked at $683K in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.